Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q1 FY24 results · Apr–Jun 2023
Lincoln Pharmaceuticals reported revenue from operations of ₹135.62 crore (up 9.8% from Q1 FY23) and net profit of ₹19.01 crore (up 26.7% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 135.62 | 123.47 | +9.8% | 112.46 | +20.6% |
| Other income | 7.69 | 6.49 | +18.4% | 3.90 | +97.2% |
| Total income | 143.31 | 129.97 | +10.3% | 116.36 | +23.2% |
| Profit before tax | 25.45 | 20.93 | +21.6% | 16.98 | +49.9% |
| Net profit for the period | 19.01 | 15.01 | +26.7% | 12.56 | +51.4% |
| EPS, basic (₹) | 9.49 | 7.49 | +26.7% | 6.27 | +51.4% |
| Net margin (%) | 14.0 | 12.2 | 11.2 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 135.62 | 123.47 | +9.8% | 112.46 | +20.6% |
| Other income | 7.69 | 6.49 | +18.4% | 3.95 | +94.9% |
| Total income | 143.31 | 129.97 | +10.3% | 116.41 | +23.1% |
| Profit before tax | 25.45 | 20.93 | +21.6% | 16.98 | +49.9% |
| Net profit for the period | 19.01 | 15.01 | +26.7% | 12.56 | +51.4% |
| EPS, basic (₹) | 9.49 | 7.49 | +26.7% | 6.27 | +51.4% |
| Net margin (%) | 14.0 | 12.2 | 11.2 |
Consolidated
- Filed with BSE
- 10 Aug 2023, 12:49 IST
- Board meeting
- 10 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Aug 2023, 12:49 IST
- Board meeting
- 10 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE